Kingdon Capital Management L.L.C. Has $1,291,000 Stake in Jaguar Animal Health, Inc. (JAGX)

Kingdon Capital Management L.L.C. held its stake in Jaguar Animal Health, Inc. (NASDAQ:JAGX) during the first quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund owned 1,297,815 shares of the biotechnology company’s stock at the end of the first quarter. Kingdon Capital Management L.L.C. owned 0.09% of Jaguar Animal Health worth $1,291,000 at the end of the most recent reporting period.

Separately, Vanguard Group Inc. increased its stake in Jaguar Animal Health by 49.6% in the first quarter. Vanguard Group Inc. now owns 115,922 shares of the biotechnology company’s stock worth $116,000 after buying an additional 38,447 shares during the period. 24.72% of the stock is owned by institutional investors.

Jaguar Animal Health, Inc. (JAGX) traded down 1.64% during midday trading on Friday, reaching $0.60. The company’s stock had a trading volume of 64,115 shares. The firm has a 50-day moving average price of $0.72 and a 200 day moving average price of $0.81. Jaguar Animal Health, Inc. has a 52-week low of $0.50 and a 52-week high of $2.98. The stock’s market capitalization is $8.66 million.

ILLEGAL ACTIVITY NOTICE: This piece of content was first published by sleekmoney and is owned by of sleekmoney. If you are accessing this piece of content on another publication, it was illegally stolen and reposted in violation of U.S. & international copyright and trademark law. The correct version of this piece of content can be accessed at https://sleekmoney.com/kingdon-capital-management-l-l-c-has-1291000-stake-in-jaguar-animal-health-inc-jagx/1916272.html.

About Jaguar Animal Health

Jaguar Animal Health, Inc is an animal health company. It is focused on developing and commercializing gastrointestinal products for companion and production animals, foals, and horses. Canalevia is its prescription drug product candidate, intended for treatment of various forms of diarrhea in dogs. Canalevia is a canine-specific formulation of crofelemer, an active pharmaceutical ingredient (API) isolated and purified from the Croton lechleri tree.

Want to see what other hedge funds are holding JAGX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Jaguar Animal Health, Inc. (NASDAQ:JAGX).

This story was originally published by sleekmoney (https://sleekmoney.com) and is the sole property of sleekmoney. If you are reading this article on another website, that means this article was illegally copied and re-published to this website in violation of U.S. and International copyright law. You can view the original version of this story at https://sleekmoney.com/kingdon-capital-management-l-l-c-has-1291000-stake-in-jaguar-animal-health-inc-jagx/1916272.html

Receive News & Ratings for Jaguar Animal Health Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Jaguar Animal Health Inc. and related companies with MarketBeat.com's FREE daily email newsletter.

 

Leave a Reply

Your email address will not be published. Required fields are marked *